Identification of PPARgamma Partial Agonists of Natural Origin (II): In Silico Prediction in Natural Extracts with Known Antidiabetic Activity

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Guasch, Laura ^a   Sala, Esther ^a   Mulero, Miquel ^a   Valls, Cristina ^a   Salvadó, Maria Josepa ^a   Pujadas, Gerard ^a,b   Garcia Vallvé, Santiago ^a,b  

^a UNIVERSITAT ROVIRA I VIRGILI   (Spain)

^b TECNIO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

2',5,6' TRIHYDROXY 6,7,8 TRIMETHOXYFLAVONE; 2,2',4,6,6' PENTAMETHOXYBIPHENYL; 3 [4 (1H INDOL 3 YL) 2,3,5,6 TETRAMETHOXYPHENYL] 7 (3 METHYL 2 BUTEN 1 YL) 1H INDOLE; 5 HYDROXY 2',3',7,8 TETRAMETHOXYFLAVONE; 7 HYDROXY 3,5,8 TRIMETHOXYFLAVONE; ANNONA PURPUREA EXTRACT; ANTIDIABETIC AGENT; ARTOCARPUS GOMEZIANUS EXTRACT; BAZOUANTHRONE; BIPHENYL DERIVATIVE; CARBOLINE DERIVATIVE; CRYPTOLEPICARBOLINE; CRYPTOTANSHINONE; DEOXYNEOCRYPTOTANSHINONE; FLAVONE DERIVATIVE; HELICHRYSUM MIXTUM EXTRACT; HELICHRYSUM ODORATISSIMUM EXTRACT; HELICHRYSUM STENOPTERUM EXTRACT; HERICERIN; INDOLE DERIVATIVE; MELICOPE PTELEFOLIA EXTRACT; MELICOPE SIMPLEX EXTRACT; MILTIONONE I; MURRAYA EXOTICA EXTRACT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PLANT EXTRACT; PLANT MEDICINAL PRODUCT; SALVIA LANIGERA EXTRACT; UNCLASSIFIED DRUG; UNINDEXED DRUG; XANTHOANGELOL F;

ACRADENIA FRANKLINII; ANNONA PURPUREA; ANTIDIABETIC ACTIVITY; ARTICLE; ARTOCARPUS GOMEZIANUS; COMPUTER MODEL; CONTROLLED STUDY; DRUG DETERMINATION; DRUG MECHANISM; DRUG SCREENING; DRUG STRUCTURE; EUODIA LUNUANKENDA; EVODIA ELLERYANA; HELICHRYSUM MIXTUM; HELICHRYSUM ODORATISSIMUM; HELICHRYSUM STENOPTERUM; MEDICINAL PLANT; MELICOPE PTELEFOLIA; MELICOPE SIMPLEX; MURRAYA EXOTICA; SALVIA ERIOPHORA; SALVIA LANIGERA; SALVIA PRIONITIS; SENSITIVITY AND SPECIFICITY; SWERTIA HOOKERI; TEPHROSIA WATSONIANA; VALIDATION STUDY; VIRTUAL REALITY;

BIOLOGICAL AGENTS; COMPUTER SIMULATION; DIABETES MELLITUS, TYPE 2; DRUG DISCOVERY; HUMANS; HYPOGLYCEMIC AGENTS; MOLECULAR STRUCTURE; PLANT EXTRACTS; PPAR GAMMA; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84873562635     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0055889     Document Type: Article

References (89)

1. Simmonds MSJ, Howes M-JR (2005) Plants Used in the Treatment of Diabetes. In: Soumyanath A, editor. Traditional Medicines for Modern Times. Antidiabetic Plants. Taylor & Francis. pp. 19-82.
2. Bnouham M, Ziyyat A, Mekhfi H, Tahri A, Legssyer A, (2006) Medicinal plants with potential antidiabetic activity- A review of ten years of herbal medicine research (1990-2000). Int J Diabetes & Metab 14: 1-25.
3. Modak M, Dixit P, Londhe J, Ghaskadbi S, Devasagayam TP, (2007) Indian herbs and herbal drugs used for the treatment of diabetes. J Clin Biochem Nutr 40: 163-173.
4. Grover JK, Yadav S, Vats V, (2002) Medicinal plants of India with anti-diabetic potential. J Ethnopharmacol 81: 81-100.
5. Luo J, Fort DM, Carlson TJ, Noamesi BK, nii-Amon-Kotei D, et al. (1998) Cryptolepis sanguinolenta: an ethnobotanical approach to drug discovery and the isolation of a potentially useful new antihyperglycaemic agent. Diabet Med 15: 367-374 doi:10.1002/(SICI)1096-9136(199805)15:5<367::AID-DIA576>3.0.CO;2-G.
6. Christensen KB, Minet A, Svenstrup H, Grevsen K, Zhang H, et al. (2009) Identification of plant extracts with potential antidiabetic properties: effect on human peroxisome proliferator-activated receptor (PPAR), adipocyte differentiation and insulin-stimulated glucose uptake. Phytother Res 23: 1316-1325 doi:10.1002/ptr.2782.
7. Berger J, Moller DE, (2002) The mechanisms of action of PPARs. Annu Rev Med 53: 409-435 doi:10.1146/annurev.med.53.082901.104018.
8. Shearer BG, Billin AN, (2007) The next generation of PPAR drugs: do we have the tools to find them? Biochim Biophys Acta 1771: 1082-1093 doi:10.1016/j.bbalip.2007.05.005.
9. Feldman PL, Lambert MH, Henke BR, (2008) PPAR modulators and PPAR pan agonists for metabolic diseases: the next generation of drugs targeting peroxisome proliferator-activated receptors? Curr Top Med Chem 8: 728-749.
10. Pourcet B, Fruchart J-C, Staels B, Glineur C, (2006) Selective PPAR modulators, dual and pan PPAR agonists: multimodal drugs for the treatment of type 2 diabetes and atherosclerosis. Expert Opin Emerg Drugs 11: 379-401 doi:10.1517/14728214.11.3.379.
11. Guasch L, Sala E, Valls C, Blay M, Mulero M, et al. (2011) Structural insights for the design of new PPARgamma partial agonists with high binding affinity and low transactivation activity. J Comput Aided Mol Des 25: 717-728 doi:10.1007/s10822-011-9446-9.
12. Guasch L, Sala E, Valls C, Mulero M, Pujadas G, et al. (2012) Development of docking-based 3D-QSAR models for PPARgamma full agonists. J Mol Graph Model 36: 1-9 doi:10.1016/j.jmgm.2012.03.001.
13. Dey D, Medicherla S, Neogi P, Gowri M, Cheng J, et al. (2003) A novel peroxisome proliferator-activated gamma (PPAR gamma) agonist, CLX-0921, has potent antihyperglycemic activity with low adipogenic potential. Metabolism 52: 1012-1018.
14. Puhl AC, Bernardes A, Silveira RL, Yuan J, Campos JLO, et al. (2012) Mode of peroxisome proliferator-activated receptor γ activation by luteolin. Mol Pharmacol 81: 788-799 doi:10.1124/mol.111.076216.
15. Weidner C, De Groot JC, Prasad A, Freiwald A, Quedenau C, et al. (2012) Amorfrutins are potent antidiabetic dietary natural products. Proc Natl Acad Sci U S A 109: 7257-7262 doi:10.1073/pnas.1116971109.
16. Fakhrudin N, Ladurner A, Atanasov AG, Heiss EH, Baumgartner L, et al. (2010) Computer-aided discovery, validation, and mechanistic characterization of novel neolignan activators of peroxisome proliferator-activated receptor gamma. Mol Pharmacol 77: 559-566 doi:10.1124/mol.109.062141.
17. Petersen RK, Christensen KB, Assimopoulou AN, Fretté X, Papageorgiou VP, et al. (2011) Pharmacophore-driven identification of PPARγ agonists from natural sources. J Comput Aided Mol Des 25: 107-116 doi:10.1007/s10822-010-9398-5.
18. Guasch L, Sala E, Castell-Auví A, Cedó L, Liedl KR, et al. (2012) Identification of PPARgamma Partial Agonists of Natural Origin (I): Development of a Virtual Screening Procedure and In Vitro Validation. PLoS ONE 7: e50816 doi:10.1371/journal.pone.0050816.
19. Huang N, Shoichet BK, Irwin JJ, (2006) Benchmarking sets for molecular docking. J Med Chem 49: 6789-6801 doi:10.1021/jm0608356.
20. Eidi M, Eidi A, Zamanizadeh H, (2005) Effect of Salvia officinalis L. leaves on serum glucose and insulin in healthy and streptozotocin-induced diabetic rats. J Ethnopharmacol 100: 310-313 doi:10.1016/j.jep.2005.03.008.
21. Tan Y, Kamal MA, Wang Z-Z, Xiao W, Seale JP, et al. (2011) Chinese herbal extracts (SK0506) as a potential candidate for the therapy of the metabolic syndrome. Clin Sci (Lond) 120: 297-305 doi:10.1042/CS20100441.
22. Perfumi M, Arnold N, Tacconi R, (1991) Hypoglycemic activity of Salvia fruticosa Mill. from Cyprus. J Ethnopharmacol 34: 135-140.
23. Jimenez J, Risco S, Ruiz T, Zarzuelo A, (1986) Hypoglycemic activity of Salvia lavandulifolia. Planta Med pp. 260-262.
24. Jung SH, Seol HJ, Jeon SJ, Son KH, Lee JR, (2009) Insulin-sensitizing activities of tanshinones, diterpene compounds of the root of Salvia miltiorrhiza Bunge. Phytomedicine 16: 327-335 doi:10.1016/j.phymed.2008.12.017.
25. Waisundara VY, Hsu A, Huang D, Tan BK-H, (2008) Scutellaria baicalensis enhances the anti-diabetic activity of metformin in streptozotocin-induced diabetic Wistar rats. Am J Chin Med 36: 517-540.
26. Nishioka T, Kawabata J, Aoyama Y, (1998) Baicalein, an alpha-glucosidase inhibitor from Scutellaria baicalensis. J Nat Prod 61: 1413-1415 doi:10.1021/np980163p.
27. Sharaf MHM, Schiff PL, Tackie AN, Phoebe CH, Howard L, et al. (1995) Submicromole structure elucidation: Cryptolepicarboline-a novel dimeric alkaloid from Cryptolepis sanguinolenta. Magn Reson Chem 33: 767-778.
28. Bierer DE, Dubenko LG, Zhang P, Lu Q, Imbach PA, et al. (1998) Antihyperglycemic activities of cryptolepine analogues: an ethnobotanical lead structure isolated from Cryptolepis sanguinolenta. J Med Chem 41: 2754-2764 doi:10.1021/jm970735n.
29. Zhang Y, Li Y, Guo Y, Jiang H, Shen X, (2009) A sesquiterpene quinone, dysidine, from the sponge Dysidea villosa, activates the insulin pathway through inhibition of PTPases. Acta Pharmacol Sin 30: 333-345 doi:10.1038/aps.2009.5.
30. Enoki T, Ohnogi H, Nagamine K, Kudo Y, Sugiyama K, et al. (2007) Antidiabetic activities of chalcones isolated from a Japanese Herb, Angelica keiskei. J Agric Food Chem 55: 6013-6017 doi:10.1021/jf070720q.
31. Choi JH, Banks AS, Estall JL, Kajimura S, Boström P, et al. (2010) Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5. Nature 466: 451-456 doi:10.1038/nature09291.
32. Choi JH, Banks AS, Kamenecka TM, Busby SA, Chalmers MJ, et al. (2011) Antidiabetic actions of a non-agonist PPARγ ligand blocking Cdk5-mediated phosphorylation. Nature 477: 477-481 doi:10.1038/nature10383.
33. Tian L-Y, Bai X, Chen X-H, Fang J-B, Liu S-H, et al. (2010) Anti-diabetic effect of methylswertianin and bellidifolin from Swertia punicea Hemsl. and its potential mechanism. Phytomedicine 17: 533-539 doi:10.1016/j.phymed.2009.10.007.
34. Basnet P, Kadota S, Shimizu M, Namba T, (1994) Bellidifolin: a potent hypoglycemic agent in streptozotocin (STZ)-induced diabetic rats from Swertia japonica. Planta Med 60: 507-511 doi:10.1055/s-2006-959560.
35. Chandrasekar B, Bajpai MB, Mukherjee SK, (1990) Hypoglycemic activity of Swertia chirayita (Roxb ex Flem) Karst. Indian J Exp Biol 28: 616-618.
36. Lagorce D, Sperandio O, Galons H, Miteva MA, Villoutreix BO, (2008) FAF-Drugs2: free ADME/tox filtering tool to assist drug discovery and chemical biology projects. BMC Bioinformatics 9: 396 doi:10.1186/1471-2105-9-396.
37. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ, (2001) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 46: 3-26.
38. Dixon SL, Smondyrev AM, Knoll EH, Rao SN, Shaw DE, et al. (2006) PHASE: a new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results. J Comput Aided Mol Des 20: 647-671 doi:10.1007/s10822-006-9087-6.
39. Sala E, Guasch L, Iwaszkiewicz J, Mulero M, Salvadó M-J, et al. (2011) Identification of human IKK-2 inhibitors of natural origin (part I): modeling of the IKK-2 kinase domain, virtual screening and activity assays. PLoS ONE 6: e16903 doi:10.1371/journal.pone.0016903.
40. Sala E, Guasch L, Iwaszkiewicz J, Mulero M, Salvadó M-J, et al. (2011) Identification of human IKK-2 inhibitors of natural origin (Part II): in Silico prediction of IKK-2 inhibitors in natural extracts with known anti-inflammatory activity. Eur J Med Chem 46: 6098-6103 doi:10.1016/j.ejmech.2011.09.022.
41. Guasch L, Ojeda MJ, González-Abuín N, Sala E, Cereto-Massagué A, et al. (2012) Identification of novel human dipeptidyl peptidase-IV inhibitors of natural origin (part I): virtual screening and activity assays. PLoS ONE 7: e44971 doi:10.1371/journal.pone.0044971.
42. Guasch L, Sala E, Ojeda MJ, Valls C, Bladé C, et al. (2012) Identification of novel human dipeptidyl peptidase-IV inhibitors of natural origin (Part II): in silico prediction in antidiabetic extracts. PLoS ONE 7: e44972 doi:10.1371/journal.pone.0044972.
43. Guex N, Peitsch MC, (1997) SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling. Electrophoresis 18: 2714-2723 doi:10.1002/elps.1150181505.
44. Zsoldos Z, Reid D, Simon A, Sadjad SB, Johnson AP, (2007) eHiTS: a new fast, exhaustive flexible ligand docking system. J Mol Graph Model 26: 198-212 doi:10.1016/j.jmgm.2006.06.002.
45. Cousins KR, (2011) Computer review of ChemDraw Ultra 12.0. J Am Chem Soc 133: 8388 doi:10.1021/ja204075s.
46. Schuster D, Wolber G, (2010) Identification of bioactive natural products by pharmacophore-based virtual screening. Curr Pharm Des 16: 1666-1681.
47. Duan J, Dixon SL, Lowrie JF, Sherman W, (2010) Analysis and comparison of 2D fingerprints: insights into database screening performance using eight fingerprint methods. J Mol Graph Model 29: 157-170 doi:10.1016/j.jmgm.2010.05.008.
48. Kelley LA, Gardner SP, Sutcliffe MJ, (1996) An automated approach for clustering an ensemble of NMR-derived protein structures into conformationally related subfamilies. Protein Eng 9: 1063-1065.
49. Mesquita AAL, Corrêa DDB, De Pádua AP, Guedes MLO, Gottlieb OR, (1986) Flavonoids from four compositae species. Phytochemistry 25: 1255-1256 doi:10.1016/S0031-9422(00)81599-X.
50. Arredondo MF, Blasina F, Echeverry C, Morquio A, Ferreira M, et al. (2004) Cytoprotection by Achyrocline satureioides (Lam) D.C. and some of its main flavonoids against oxidative stress. J Ethnopharmacol 91: 13-20 doi:10.1016/j.jep.2003.11.012.
51. Koteswara Rao Y, Vimalamma G, Rao CV, Tzeng Y-M, (2004) Flavonoids and andrographolides from Andrographis paniculata. Phytochemistry 65: 2317-2321 doi:10.1016/j.phytochem.2004.05.008.
52. Jahan N, Malik A, Muhammad P, (2001) New Flavonoid from Mentha longifolia. Heterocycles 55: 1951-1955.
53. Wibudi A, Kiranadi B, Manalu W, winarto A, Suyono S, (2008) The traditional plant, Andrographis paniculata (Sambiloto), exhibits insulin-releasing actions in vitro. Acta Med Indones 40: 63-68.
54. Nishimura R, Tabata K, Arakawa M, Ito Y, Kimura Y, et al. (2007) Isobavachalcone, a chalcone constituent of Angelica keiskei, induces apoptosis in neuroblastoma. Biol Pharm Bull 30: 1878-1883.
55. Matsuura M, Kimura Y, Nakata K, Baba K, Okuda H, (2001) Artery relaxation by chalcones isolated from the roots of Angelica keiskei. Planta Med 67: 230-235 doi:10.1055/s-2001-12011.
56. Arai K, Shimizu S, Yamamoto Y, (1981) Metabolic Products of Aspregillus terreus. VI. Metabolites of the Strain IFO 8835. (3). The Isolation and Chemical Structures of Colorless Metabolites. Chem Pharm Bull 29: 1005-1012.
57. Dewi RT, Iskandar YM, Hanafi M, Kardono LBS, Angelina M, et al. (2007) Inhibitory effect of koji Aspergillus terreus on alpha-glucosidase activity and postprandial hyperglycemia. Pak J Biol Sci 10: 3131-3135.
58. Sharaf MHM, Schiff PL, Tackie AN, Phoebe CH, Johnson RL, et al. (1996) The isolation and structure determination of cryptomisrine, a novel indolo[3,2- b]quinoline dimeric alkaloid from cryptolepis sanguinolenta. J Heterocycl Chem 33: 789-797 doi:10.1002/jhet.5570330343.
59. Stewart M, Fell PM, Blunt JW, Munro MHG, (1997) Avarol and Related Compounds from the New Zealand Marine Sponge Dysidea sp. Aust J Chem 50: 341-348.
60. Glombitza K-W, Lentz G, (1981) Antibiotics from algae-XXVIII: Cleavage of high molecular phlorotannin derivatives from the brown alga fucus vesiculosus L. Tetrahedron 37: 3861-3866 doi:10.1016/S0040-4020(01)98884-2.
61. Lamela M, Anca J, Villar R, Otero J, Calleja JM, (1989) Hypoglycemic activity of several seaweed extracts. J Ethnopharmacol 27: 35-43.
62. Lenta B, Ngouela S, Boyom F, Tantangmo F, Tchouya G, et al. (2007) Anti-plasmodial activity of some constituents of the root bark of Harungana madagascariensis LAM. (Hypericaceae). Chem Pharm Bull 55: 464-467.
63. Agbor GA, Kuate D, Oben JE, (2007) Medicinal plants can be good source of antioxidants: case study in Cameroon. Pak J Biol Sci 10: 537-544.
64. Kimura Y, Nishibe M, Nakajima H, Hamasaki T, Shimada A, et al. (1991) Hericerin, a New Pollen Growth Inhibitor from the Mushroom Hericium erinaceum. Agric Biol Chem 55: 2673-2674.
65. Michihiro F, Nobuaki E, Ken'ichi M, (2006) Utility and Function of Mushrooms Neuroprotective Effect of Hericium erinaceum. Foods & Food Ingred J Jpn 211: 141-147.
66. Ikeshiro Y, Hashimoto I, Iwamoto Y, Mase I, Tomita Y, (1991) Diterpenoids from Salvia miltiorrhiza. Phytochemistry 30: 2791-2792 doi:10.1016/0031-9422(91)85147-R.
67. Ikeshiro Y, Mase I, Tomita Y, (1989) Abietane type diterpenoids from Salvia miltiorrhiza. Phytochemistry 28: 3139-3141 doi:10.1016/0031-9422(89)80294-8.
68. Chemesova II, Iinuma M, Budantsev AL, (1993) Investigation of the flavonoid composition of Scutellaria adenostegia. Chem Nat Compd 29: 133-134 doi:10.1007/BF00631041.
69. Prabhakar PK, Doble M, (2011) Mechanism of action of natural products used in the treatment of diabetes mellitus. Chin J Integr Med 17: 563-574 doi:10.1007/s11655-011-0810-3.
70. Chang FR, Wei JL, Teng CM, Wu YC, (1998) Two new 7-dehydroaporphine alkaloids and antiplatelet action aporphines from the leaves of Annona purpurea. Phytochemistry 49: 2015-2018.
71. Shirwaikar A, Rajendran K, Dinesh Kumar C, Bodla R, (2004) Antidiabetic activity of aqueous leaf extract of Annona squamosa in streptozotocin-nicotinamide type 2 diabetic rats. J Ethnopharmacol 91: 171-175 doi:10.1016/j.jep.2003.12.017.
72. Likhitwitayawuid K, Sritularak B, De-Eknamkul W, (2000) Tyrosinase inhibitors from Artocarpus gomezianus. Planta Med 66: 275-277 doi:10.1055/s-2000-8656.
73. Fernando MR, Thabrew MI, Karunanayake EH, (1990) Hypoglycaemic activity of some medicinal plants in Sri-Lanka. Gen Pharmacol 21: 779-782.
74. Jakupovic J, Kuhnke J, Schuster A, Metwally MA, Bohlmann F, (1986) Phloroglucinol derivatives and other constituents from South African Helichrysum species. Phytochemistry 25: 1133-1142 doi:10.1016/S0031-9422(00)81569-1.
75. Aslan M, Deliorman Orhan D, Orhan N, Sezik E, Yesilada E, (2007) In vivo antidiabetic and antioxidant potential of Helichrysum plicatum ssp. plicatum capitulums in streptozotocin-induced-diabetic rats. J Ethnopharmacol 109: 54-59 doi:10.1016/j.jep.2006.07.001.
76. Hänsel R, Cybulski E-M, Çubukçu B, Meriçli AH, Bohlmann F, et al. (1980) Neue pyron-derivate aus Helichrysum-arten. Phytochemistry 19: 639-644 doi:10.1016/0031-9422(80)87030-0.
77. Kamperdick C, Van NH, Sung TV, Adam G, (1997) Benzopyrans from Melicope ptelefolia leaves. Phytochemistry 45: 1049-1056 doi:10.1016/S0031-9422(97)00059-9.
78. Yeo J, Kang Y-M, Cho S-I, Jung M-H, (2011) Effects of a multi-herbal extract on type 2 diabetes. Chin Med 6: 10 doi:10.1186/1749-8546-6-10.
79. Briggs LH, Locker RH, (1950) 486. Chemistry of New Zealand Melicope species. Part IV. Constituents of the bark of Melicope simplex. J Chem Soc pp. 2376-2379 doi:10.1039/JR9500002376.
80. Kinoshita T, Wu J-B, Ho F-C, (1996) Prenylcoumarins from Murraya paniculata var. omphalocarpa (Rutaceae): The Absolute Configuration of Sibiricin, Mexoticin and Omphamurin. Chem Pharm Bull 44: 1208-1211.
81. El-Lakany AM, (2003) Two new diterpene quinones from the roots of Salvia lanigera Poir. Pharmazie 58: 75-76.
82. Li M, Zhang JS, Chen MQ, (2001) A novel dimeric diterpene from Salvia prionitis. J Nat Prod 64: 971-972.
83. Ulubelen A, Birman H, Oksüz S, Topçu G, Kolak U, et al. (2002) Cardioactive diterpenes from the roots of Salvia eriophora. Planta Med 68: 818-821 doi:10.1055/s-2002-34408.
84. Blasko G, Lin L-Z, Cordell GA (n.d.) Determination of a new tetracyclic diterpene skeleton through selective INEPT spectroscopy. J Org Chem 53: 6113-6115.
85. Ghosal S, Biswas K, Jaiswal DK, (1980) Xanthone and flavonol constituents of Swertia hookeri. Phytochemistry 19: 123-126 doi:10.1016/0031-9422(80)85027-8.
86. Basnet P, Kadota S, Shimizu M, Takata Y, Kobayashi M, et al. (1995) Bellidifolin stimulates glucose uptake in rat 1 fibroblasts and ameliorates hyperglycemia in streptozotocin (STZ)-induced diabetic rats. Planta Med 61: 402-405 doi:10.1055/s-2006-958124.
87. Negi JS, Singh P, Pant GJ, Rawat MSM, (2010) RP-HPLC analysis and antidiabetic activity of Swertia paniculata. Nat Prod Commun 5: 907-910.
88. Gómez F, Quijano L, Calderón JS, Rodríquez C, Ríos T, (1985) Prenylflavans from Tephrosia watsoniana. Phytochemistry 24: 1057-1059 doi:10.1016/S0031-9422(00)83182-9.
89. Pavana P, Manoharan S, Renju GL, Sethupathy S, (2007) Antihyperglycemic and antihyperlipidemic effects of Tephrosia purpurea leaf extract in streptozotocin induced diabetic rats. J Environ Biol 28: 833-837.